Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: Identification of a novel atypical neuroleptic

Journal of Medicinal Chemistry

Volumn 40, Issue 25, 1997, Pages 4146-4153

  Liao, Yi ^a   DeBoer, Peter ^a   Meier, Eddie ^b   Wikström, Håkan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 (TRIFLUOROMETHANESULFONYLOXY) 11 (4 METHYLPIPERAZINO) 5H DIBENZO[B,E][1,4]DIAZEPINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GMC1 169; MUSCARINIC RECEPTOR; UNCLASSIFIED DRUG;

ANTICHOLINERGIC EFFECT; ARTICLE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; MALE; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031443519     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9704457     Document Type: Article

References (54)

1. Carlsson, A.; Lindqvist, M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normethanephrine in mouse brain. Acta Pharmacol. Toxicol. 1963, 20, 140-144.
2. Creese, I.; Burt, D.; Snyder, S. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192, 481-483.
3. Seeman, P.; Lee, T.; Choa-Wong, M.; Wong, K. Antipsychotic drug dose and neuroleptic/dopamine receptors. Nature 1976, 261, 717-719.
4. Richelson, E.; Nelson, A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol. 1984, 103, 197-204.
5. Delay, J.; Deniker, P.; Harl, J.-M. Traitment des etats d'excitation et d'agitation par une methode medicamenteuse derivée de l'hibernotherapie. Ann. Med. Psychol. 1952, 110, 267-273.
6. Deniker, P. Discovery of the clinical use of neuroleptics. In Discoveries in Pharmacology, Vol 1: Psycho- and neuropharmacology; Parnam, M., Bruinvels, J., Eds.; Elservier: Amsterdam, 1983; pp 163-180.
7. Janssen, P.; Van Bever, W. Structure-activity relationships of the butyrophenones and diphenylbutylpiperidines. In Handbook of psychopharmacology; Iversen, L., Iversen S., Snyder, S. H., Eds.; Plenum Press: New York, 1978; Vol. 10, pp 1-36.
8. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 1988, 45, 789-796.
9. Kane, J. Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. Drugs 1993, 46, 585-593.
10. Meltzer, H.; Matsubara, S.; Lee, J. C. Classification of typical and antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
11. Baldessarini, R.; Frankenburg, F. Clozapine: a novel anti-psychotic agent. New Engl. J. Med. 1991, 324, 746-754.
12. Idänpäan-Heikkilä, J.; Alhava, E.; Olkinuora, M.; Palva, P. Agranulocytosis during treatment of clozapine. Eur. J. Clin. Pharmacol. 1977, 11, 193-198.
13. Lieberman, J. A.; Johns, C. A.; Kane, J. M.; Rai, K.; Pisciotta, A. V.; Saltz, B. L.; Howard, A. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J. Clin. Psychiatry 1988, 49, 271-277.
14. Alvir, J. M. J.; Lieberman, J. A.; Safferman, A.; Schwimmer, J. L.; Schaaf, J. A. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. New Engl. J. Med. 1993, 329, 162-167.
15. Buchanan, R. W. Clozapine: efficacy and safety. Schizophrenia Bull. 1995, 21, 579-591.
16. Casey, D. E. Side effect profiles of new antipsychotic agents. J. Clin. Psychiatry 1996, 57, 40-52.
17. Lindström, L. H. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scand. 1988, 77, 524-529.
18. Wilson, W. H.; Claussen, A. M. Seizures associated with clozapine treatment in a state hospital. J. Clin. Psych. 1994, 55, 184-188.
19. Leysen, J. E.; Gommeren, W.; Eens, A.; de Chaffoy de Courcelles, D.; Stoof, J. C.; Janssen, P. A. Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther. 1988, 247, 661-670.
20. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350, 610.
21. 4 receptors evaluated in schizophrenia. Nature 1993, 365, 441-445.
22. 1 receptor agonist? Eur. J. Pharmacol. 1995, 282, 137-144.
23. Liégelois, J.-F. F.; Rogister, F. A.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Inarejos, M.-O.; Chleide, E. M. G.; Mercier, M. G. A.; Delarge, J. E. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study. J. Med. Chem. 1994, 37, 519-525.
24. Liégelois, J.-F. F.; Bruhwyler, J.; Rogister, F. A.; Delarge, J. E. Diarylazepine derivatives as potential atypical neuroleptic drugs: Recent Advances. Curr. Med. Chem. 1995, 1, 471-501.
25. Phillips, S. T.; de Paulis, T.; Baron, B. M.; Siegel, B. W.; Seeman, P.; Van Tol, H. H. M.; Guan, H.-C.; Smith, H. E. Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptene analogues of clozapine to dopamine and serotonin receptors. J. Med. Chem. 1994, 37, 2686-2696.
26. Fuller, R. W.; Snoddy, H. D. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by Olanzapine (LY-170, 053), an antipsychotic drug candidate. Res. Commun. Chem. Pathol. Pharmacol. 1992, 77, 87-93.
27. Moore, N. A.; Calligaro, D. O.; Wong, D. T.; Bymaster, F.; Tye, N. C. The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs 1993, 2, 281-293.
28. Goldstein, J. M.; Arvanitis, L. A. ICI 204,636 (Seroquel): A dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Rev. 1995, 1, 50-73.
29. Schmutz, J. Neuroleptic piperazinyl-dibenzo-azepines. Chemistry and structure-activity relationships. Arzneim.-Forsch. 1975, 25, 712-720.
30. Streitweiser, A.; Dafforn, A. Solvolysis of aryl trifluoromethanesulfonates. Tetrahedron Lett. 1976, 18, 1435-1438.
31. 1D receptor ligands. ISBN 90 367 0681 5; NUGI 746.
32. 1D receptor agonist properties of novel 2-[5-(trifluoromethyl-sulfonyloxy)-indolyl)ethylamines and their use as synthetic intermediates. J. Med. Chem. 1996, 39, 4717-4726.
33. Sonesson, C.; Waters, N.; Svensson, K.; Carlsson, A.; Smith, M. W.; Piercey, M. F.; Meier, E.; Wikström, H. Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J. Med. Chem. 1993, 36, 3188-3196.
34. Sonesson, C.; Boije, M.; Svensson, K.; Ekman, A.; Carlsson, A.; Romero, A. G.; Martin, I. J.; Duncan, J. N.; King, L. J.; Wikström, H. Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino) tetralins and the formation of active metabolites in vivo. J. Med. Chem. 1993, 36, 3409-3416.
35. Sonesson, C.; Barf, T.; Nilsson, J.; Dijkstra, D.; Carlsson, A.; Svensson, K.; Smith, M. W.; Martin, I. J.; Duncan, J. N.; King, L. J.; Wikström, H. Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogues of 5-, 7- and 8-trifluoromethylsulfonyloxy-2-aminotetralins. J. Med. Chem. 1995, 38, 8, 1319-1329.
36. Haadsma-Svensson, S. R.; Smith, M. W.; Lin, C. H.; Duncan, J. N.; Sonesson, C.; Wikström, H.; Waters, N.; Carlsson, A.; Svensson, K. Synthesis and biological activity of C-5 modified derivatives of (+)-AJ76 and (+)-UH232: increased dopamine D3 receptor preference and improved pharmacokinetic properties. Bioorg. Med. Chem. Lett. 1994, 4, 689-694.
37. Hunziker, F.; Lauener, H.; Schmutz, J. 11-Dialkylamino-5-dibenzo[b,e][1,4] diazepines. Patent No. Fr. 1,334,944 (CI. A 61k, C 07d). Assignee: Wander, A. A.-G. 1963 (Chem. Abstr. 1961, 61, 3127d).
38. Hunziker, F.; Lauener, H.; Schmutz, J. Zur chemie und Pharmakologie von in 10-stellung basisch substituierten 5-Dibenzo-[b,e][1,4]-diazepin-derivaten. Arzneim.-Forseh. 1963, 13, 324-328.
39. Gerson, S. L.; Arce, C.; Meltzer, H. Y. N-Demethylclozapine: a clozapine metabolite that suppresses hemopoiesis. Br. J. Haematol. 1994, 86 (3), 555-561.
40. Stock, B.; Spiteller, G.; Heipertz, R. Exchange of aromatically bound halogens for hydroxy and methylthio groups in metabolizing clozapine in man. Arzneim.-Forsch. 1977, 27, 7 (5), 982-990.
41. Hyttel, J. Preferential labeling of adenylate cyclase coupled dopamine receptors with thioxanthene neuroleptics. In Advances in Dopamine Research: Advances in the Biosciences; Kohsaka, M., Shohmori, T., Tsukada, Y., and Woodruff, G. N., Eds.; Pergamon Press Ltd.: Oxford, 1982; Vol 37., pp 147-152.
42. 2 measures and effect of selective lesions. J. Neurol. Transm. 1987, 68, 171-189.
43. 2 receptor density in corpus striatum in mice. Acta Pharmacol. Toxicol. 1986, 59, 387-391.
44. 2 receptors in corpus striatum of rats. Pharmacol. Toxicol. 1987, 61, 126-129.
45. 1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. J. Med. Chem. 1995, 38, 4380-4392.
46. Amt, J.; Lembøl, H. L.; Meier, E.; Pedersen, H. Discriminative stimulus properties of the muscarinic receptor agonists Lu 26-046 and O-Me-THPO in rats. Evidence for involvements of different muscarinic receptor subtypes. Eur. J. Pharmacol. 1992, 218, 139-169.
47. Hyttel, J.; Larsen, J. J. Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline and serotonin. J. Neurochem. 1985, 44, 1615-1622.
48. 3-Antagonistic Properties. Drug Dev. Res. 1997, 40, 1-16.
49. 1 receptors in the brain. Life Sci. 1984, 34, 597-605.
50. 2-receptor antagonist. Drug. Dev. Res. 1988, 15, 389-404.
51. 3 receptor stimulation on locomotion and striatal dopamine levels. Brain Res. 1997, 758, 83-91.
52. Sánchez, C.; Arnt, J.; Dragsted, N.; Hyttel, J.; Lembøl, H. L.; Meier, E.; Perregaard, J.; Skarsfeldt, T. Neurochemical and in vivo pharmacological profile of Sertindole, a limbic-selective neuroleptic compound. Drug Dev. Res. 1991, 22, 239-250.
53. 3 receptors. Psychopharmacology 1994, 116, 464-468.
54. 3 receptor in rat brain cortex. Arch. Phar. Pharm. Med. Chem. 1996, 329, 413-416.